Drug
GLYX-13 peptide clinical trials
Also written Rapastinel and GLYX-13.
- studies test it
- 19
- open now
- 0
- in phase 3
- 10
- first study started
- 2009
How studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2018 (6)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 6 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 6
- Phase 3
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 2
Naurex, Inc, an affiliate of Allergan plc (17) · New York State Psychiatric Institute (1) · Northwestern University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses GLYX-13 peptide is read from its arms, and is right about nine times in ten.
Testing it · 19
- Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric IllnessTerminatedPhase 2Northwestern UniversityNCT01844726Written as GLYX-13
- Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)TerminatedPhase 3Naurex, Inc, an affiliate of Allergan plcNCT03614156Written as Rapastinel
- Study of Rapastinel as Monotherapy in Patients With MDDTerminatedPhase 3Naurex, Inc, an affiliate of Allergan plcNCT03560518Written as Rapastinel
- A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive DisorderTerminatedPhase 2Naurex, Inc, an affiliate of Allergan plcNCT03352453Written as Rapastinel
- Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)TerminatedPhase 3Naurex, Inc, an affiliate of Allergan plcNCT03675776Written as Rapastinel
- Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)TerminatedPhase 3Naurex, Inc, an affiliate of Allergan plcNCT03668600Written as Rapastinel
- Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive DisorderCompletedPhase 3Naurex, Inc, an affiliate of Allergan plcNCT03002077Written as Rapastinel
- A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive DisorderCompletedPhase 3Naurex, Inc, an affiliate of Allergan plcNCT02951988Written as Rapastinel
- A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)CompletedPhase 3Naurex, Inc, an affiliate of Allergan plcNCT02943564Written as Rapastinel
- Open Label Extension for GLYX13-C-202, NCT01684163TerminatedPhase 2Naurex, Inc, an affiliate of Allergan plcNCT02192099Written as Rapastinel (225 mg/450 mg IV administration)
- A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)CompletedPhase 3Naurex, Inc, an affiliate of Allergan plcNCT02943577Written as Rapastinel
- A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)CompletedPhase 3Naurex, Inc, an affiliate of Allergan plcNCT02932943Written as Rapastinel
- Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)WithdrawnPhase 3Naurex, Inc, an affiliate of Allergan plcNCT03855865Written as Rapastinel
- Assessment of Effect of Rapastinel on Driving PerformanceCompletedPhase 1Naurex, Inc, an affiliate of Allergan plcNCT03814733Written as Rapastinel
- Assessment of Abuse Potential of Rapastinel in HumansCompletedPhase 1Naurex, Inc, an affiliate of Allergan plcNCT03799900Written as Rapastinel
- Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive DisorderCompletedPhase 2New York State Psychiatric InstituteNCT02267629Written as Rapastinel (formerly GLYX-13)
- Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to AntidepressantsCompletedPhase 2Naurex, Inc, an affiliate of Allergan plcNCT01684163Written as GLYX-13 5 mg/kg
- Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal VolunteersCompletedPhase 1Naurex, Inc, an affiliate of Allergan plcNCT01014650Written as GLYX-13
- Single IV Dose of GLYX-13 in Patients With Treatment-Resistant DepressionCompletedPhase 2Naurex, Inc, an affiliate of Allergan plcNCT01234558Written as GLYX-13
Codes
What other systems call GLYX-13 peptide · ClinicalTrials.gg INT004869
- MeSH (NLM) C507283GLYX-13 peptideOne source NLM
- UNII (FDA) 6A1X56B95ERAPASTINELConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C507283 | GLYX-13 peptide | One source NLM |
| UNII (FDA) | 6A1X56B95E | RAPASTINEL | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.